Notably, dasatinib triggered exacerbated reversion of NKG2A expression to very low levels in the treated CML patients (Figure 1); this was correlated with faster treatment responses by dasatinib (Figure 3). This evidence concerns the gene KLRC1 and chronic myelogenous leukemia, BCR-ABL1 positive.